Co-Diagnostics (CODX) investor relations material

Company overview and business model

• Develops, manufactures, and sells reagents for molecular diagnostic tests targeting DNA/RNA, focusing on infectious diseases and genetic traits.

• Proprietary Co-Primers® technology reduces false positives in PCR amplification, enabling low-cost, high-specificity testing.

• Product portfolio includes PCR tests for COVID-19, influenza, tuberculosis, hepatitis B/C, HPV, malaria, chikungunya, dengue, and Zika, with regulatory clearances in multiple regions.

• Developed a portable PCR platform for point-of-care and at-home use, pending FDA clearance; focus shifted to a multiplex respiratory test (ABCR) for flu, COVID-19, and RSV.

• Intellectual property includes over 20 patents and proprietary algorithms, supporting applications in human diagnostics, agriculture, and vector surveillance.

Financial performance and metrics

• As of December 31, 2025, 2,095,031 shares of common stock outstanding; additional shares reserved for options, RSUs, warrants, and equity plans.

Use of proceeds and capital allocation

• Net proceeds intended for working capital, sales and marketing expansion, capital expenditures, facilities expansion, and product development.

• May allocate funds to acquisitions or debt repayment, though no binding agreements are in place.